
	Mr. Tooman is widely versed in international finance, sales, market research, business intelligence, corporate strategy, M&amp;A and investor relations. Immediately prior to his joining the executive team, Mr. Tooman had served as a Director and Chairman of Aratana&#39;s Audit Committee; he served as a member of the Board of Directors from March 2012 until his appointment as Chief Financial Officer. Mr. Tooman will also transition from his current position of CEO of Avanzar Medical, Inc., an oncology company, to focus on Aratana.
	
	Previously, Mr. Tooman held executive positions at large pharmaceutical companies, including Pharmacia and Upjohn, and served as the CFO of Enzon Pharmaceuticals and Ikaria. While at ILEX Oncology, Mr. Tooman was a member of the executive team and was instrumental in transitioning the company from a CRO into a proprietary business responsible for developing successful oncology products. This strategic transformation ultimately led to ILEX being sold to Genzyme Corporation for $1.1 billion.
